<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>12</volume><submitter>Lasagni S</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Though the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of the patients. We analyzed the clinical, histopathological, and biological features of patients with HCC to identify the predictive factors associated with cancer recurrence and survival after LT.&lt;h4>Methods&lt;/h4>We retrospectively analyzed 441 patients with HCC who underwent LT in our center. Overall, 70 (15.8%) of them developed HCC-R_LT. We matched them by age at transplant and etiology with 70 non-recurrent patients. A comparable cohort from the Liver Transplant Centre of Bologna served as validation. The clinical and biochemical characteristics and pre-LT criteria (Milan, Metroticket, Metroticket_AFP, and AFP model) were evaluated. Hist</pubmed_abstract><journal>Frontiers in oncology</journal><pagination>960808</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9493368</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation.</pubmed_title><pmcid>PMC9493368</pmcid><pubmed_authors>Gitto S</pubmed_authors><pubmed_authors>d'Errico A</pubmed_authors><pubmed_authors>Leonardi F</pubmed_authors><pubmed_authors>Romagnoli D</pubmed_authors><pubmed_authors>Pivetti A</pubmed_authors><pubmed_authors>Giannelli G</pubmed_authors><pubmed_authors>Romanzi A</pubmed_authors><pubmed_authors>Serenari M</pubmed_authors><pubmed_authors>Catellani B</pubmed_authors><pubmed_authors>Dituri F</pubmed_authors><pubmed_authors>Critelli RM</pubmed_authors><pubmed_authors>Martinez-Chantar ML</pubmed_authors><pubmed_authors>Colecchia A</pubmed_authors><pubmed_authors>Celsa C</pubmed_authors><pubmed_authors>Mancarella S</pubmed_authors><pubmed_authors>di Benedetto F</pubmed_authors><pubmed_authors>Camma C</pubmed_authors><pubmed_authors>Riefolo M</pubmed_authors><pubmed_authors>Lasagni S</pubmed_authors><pubmed_authors>Enea M</pubmed_authors><pubmed_authors>Di Marco L</pubmed_authors><pubmed_authors>Schepis F</pubmed_authors><pubmed_authors>Ravaioli F</pubmed_authors><pubmed_authors>Milosa F</pubmed_authors><pubmed_authors>de Maria N</pubmed_authors><pubmed_authors>Cescon M</pubmed_authors><pubmed_authors>Villa E</pubmed_authors><pubmed_authors>Magistri P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation.</name><description>&lt;h4>Background&lt;/h4>Though the precise criteria for accessing LT are consistently being applied, HCC recurrence (HCC-R_LT) still affects more than 15% of the patients. We analyzed the clinical, histopathological, and biological features of patients with HCC to identify the predictive factors associated with cancer recurrence and survival after LT.&lt;h4>Methods&lt;/h4>We retrospectively analyzed 441 patients with HCC who underwent LT in our center. Overall, 70 (15.8%) of them developed HCC-R_LT. We matched them by age at transplant and etiology with 70 non-recurrent patients. A comparable cohort from the Liver Transplant Centre of Bologna served as validation. The clinical and biochemical characteristics and pre-LT criteria (Milan, Metroticket, Metroticket_AFP, and AFP model) were evaluated. Hist</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022</publication><modification>2025-04-05T12:32:32.945Z</modification><creation>2025-04-05T12:32:32.945Z</creation></dates><accession>S-EPMC9493368</accession><cross_references><pubmed>36158651</pubmed><doi>10.3389/fonc.2022.960808</doi></cross_references></HashMap>